Britain and America have signed a major trade agreement that will ensure zero levies on British medicine exports going into the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has committed to increase spending on medicines through the NHS. This move guarantees that import taxes on these key exports will stay at zero for a timeframe of 36 months.
This development follows recent warnings to significantly raise tariffs on patented pharmaceutical imports, with figures discussed as high as double the cost.
"This agreement with the United Kingdom strengthens the global environment for innovative medicines and introduces long-overdue equity to transatlantic drug exports," a release noted.
Commercial Impact
Pharmaceuticals are one of the the United Kingdom's most significant goods shipped to the America, which is clearly the biggest market for leading British pharmaceutical firms.
Trade data show that in the year prior to last September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This figure accounted for 17.4% of all goods exports in that span.
"This guarantee protects work, stimulates capital expenditure and paves the way for the UK to emerge as a international leader for medical research," the Business and Trade Secretary stated.
Detailed NHS Changes
The agreement includes several key pledges from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new medicines to be too expensive by a quarter.
- Boosted Medicine Funding: There is a goal to double total health service expenditure on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must pay back to the NHS to stay within budget will be capped at fifteen percent. Previously, rebates topped twenty percent.
Industry Background
The deal takes place against a ongoing tension between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
This friction were heightened by arguments that American patients were charged several times more for the same drugs than people in the UK and Europe.
Recently, several large manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar investments have been announced toward US facilities.
One official acknowledged that the NHS had to increase expenditure on drugs, noting that its budget allocation on drugs had shrunk as a share of its overall budget over the previous ten-year period.
